Short Interest in Genprex (NASDAQ:GNPX) Declines By 95.8%

Genprex (NASDAQ:GNPX) was the recipient of a significant drop in short interest in the month of July. As of July 31st, there was short interest totaling 36,884 shares, a drop of 95.8% from the July 15th total of 884,893 shares. Based on an average daily volume of 50,133 shares, the days-to-cover ratio is currently 0.7 days. Approximately 7.3% of the shares of the company are short sold.

Genprex Price Performance

NASDAQ GNPX traded up $0.28 on Tuesday, hitting $4.47. 156,429 shares of the company’s stock were exchanged, compared to its average volume of 218,010. The firm has a market cap of $2.23 million, a price-to-earnings ratio of -0.01 and a beta of -0.88. The firm’s 50-day moving average price is $10.11 and its two-hundred day moving average price is $26.23. Genprex has a fifty-two week low of $4.00 and a fifty-two week high of $1,210.00.

Genprex (NASDAQ:GNPX) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($14.08) EPS for the quarter.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Genprex from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings restated a “sell (e+)” rating on shares of Genprex in a research report on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.

Institutional Investors Weigh In On Genprex

A number of hedge funds and other institutional investors have recently bought and sold shares of GNPX. Mayflower Financial Advisors LLC purchased a new stake in shares of Genprex during the 1st quarter worth $36,000. Manchester Financial Inc. purchased a new position in shares of Genprex in the 1st quarter valued at about $36,000. Finally, Susquehanna International Group LLP increased its holdings in shares of Genprex by 11.7% in the 3rd quarter. Susquehanna International Group LLP now owns 340,056 shares of the company’s stock valued at $58,000 after purchasing an additional 35,661 shares in the last quarter. Institutional investors and hedge funds own 14.05% of the company’s stock.

Genprex Company Profile

Genprex, Inc is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.

In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes.